Financial Survey: Capricor Therapeutics (NASDAQ:CAPR) & Immune Therapeutics (NASDAQ:IMUN)
Immune Therapeutics (OTCMKTS:IMUN) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.
Insider & Institutional Ownership
5.1% of Capricor Therapeutics shares are owned by institutional investors. 11.7% of Immune Therapeutics shares are owned by insiders. Comparatively, 16.3% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Immune Therapeutics and Capricor Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Capricor Therapeutics has a consensus price target of $8.20, indicating a potential upside of 180.82%. Given Capricor Therapeutics’ higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Immune Therapeutics.
Earnings and Valuation
This table compares Immune Therapeutics and Capricor Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Immune Therapeutics||$110,000.00||28.16||-$8.18 million||N/A||N/A|
|Capricor Therapeutics||$1.67 million||6.53||-$15.19 million||($5.20)||-0.56|
Immune Therapeutics has higher earnings, but lower revenue than Capricor Therapeutics.
This table compares Immune Therapeutics and Capricor Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Immune Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.
Capricor Therapeutics beats Immune Therapeutics on 6 of the 11 factors compared between the two stocks.
About Immune Therapeutics
Immune Therapeutics, Inc., together with its subsidiaries, focuses on the development and commercialization of therapeutic treatments for cancer, human immunodeficiency virus (HIV)/AIDS, and autoimmune and immune disorders in the United States and internationally. It develops methionine enkephalin IRT-101, a small synthetic pentapeptide; and low-dose naltrexone IRT-103, an opioid receptor antagonist that stimulates and/or regulates the immune system to treat a range of autoimmune diseases, including multiple sclerosis; immune disorders, such as Crohn's disease and cancer; and viral infections comprising HIV/AIDS. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in December 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Receive News & Ratings for Immune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.